Oxford Biomedica (LON:OXB) Posts Earnings Results

Oxford Biomedica (LON:OXB) released its earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%.

Oxford Biomedica Price Performance

Oxford Biomedica stock traded up GBX 17 during midday trading on Friday, reaching GBX 507. 373,239 shares of the stock traded hands, compared to its average volume of 1,100,051. The stock has a market cap of £613.71 million, a P/E ratio of -18.83 and a beta of 1.09. The stock’s fifty day moving average is GBX 506.56 and its 200-day moving average is GBX 574.62. The company has a quick ratio of 1.67, a current ratio of 2.21 and a debt-to-equity ratio of 273.08. Oxford Biomedica has a 12 month low of GBX 420 and a 12 month high of GBX 952.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on OXB. Royal Bank Of Canada reissued an “outperform” rating and issued a GBX 900 price target on shares of Oxford Biomedica in a report on Tuesday, September 1st. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 595 target price on shares of Oxford Biomedica in a report on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of GBX 580.85.

Insider Transactions at Oxford Biomedica

In other news, insider Roch Doliveux acquired 20,250 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The shares were acquired at an average cost of GBX 505 per share, with a total value of £102,262.50. 43.30% of the stock is currently owned by insiders.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.